<div id="readability-page-1"><p>KALA BIO (NASDAQ:KALA - Get Free Report) posted its earnings results on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter, Zacks reports.</p><h2>KALA BIO Trading Down 12.0%</h2><ul><li>Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?</li></ul><p>Shares of KALA BIO stock traded down $0.03 on Wednesday, reaching $0.20. The stock had a trading volume of 3,346,512 shares, compared to its average volume of 6,513,633. KALA BIO has a 1 year low of $0.15 and a 1 year high of $20.60. The company has a market cap of $181.17 million, a P/E ratio of -0.03 and a beta of -1.98. The business's 50 day moving average is $0.30 and its two-hundred day moving average is $0.65. </p><h2>Institutional Investors Weigh In On KALA BIO</h2><p>A number of institutional investors and hedge funds have recently modified their holdings of KALA. Woodline Partners LP purchased a new stake in shares of  KALA BIO in the first quarter worth about $1,483,000.  Jane Street Group LLC purchased a new stake in  KALA BIO in the fourth quarter valued at approximately $80,000.  Virtu Financial LLC purchased a new stake in  KALA BIO in the fourth quarter valued at approximately $48,000.  XTX Topco Ltd purchased a new stake in  KALA BIO in the second quarter valued at approximately $62,000.  Finally, Geode Capital Management LLC raised its stake in  KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after purchasing an additional 1,534 shares in the last quarter. 24.61% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>Separately, Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of KALA BIO in a report on Friday, March 27th. One analyst  has rated the stock with a Buy rating, four have assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, KALA BIO  has an average rating of &#34;Hold&#34; and a consensus price target of $20.38.</p><p><b>View Our Latest Report on KALA</b></p><h2>KALA BIO Company Profile</h2> (Get Free Report)<p>KALA Bio <span>NASDAQ: KALA<span></span></span> is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company's proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.  </p><p>Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than KALA BIO</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in KALA BIO Right Now?</h2><p>Before you consider KALA BIO, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KALA BIO wasn't on the list.</p><p>While KALA BIO currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KALA

<p>KALA BIO (NASDAQ:KALA) reported quarterly earnings of $0.86 per share. The stock fell 12% to $0.20, with a trading volume of 3.3 million shares. Institutional investors have recently increased their stakes, with 24.61% of shares owned by hedge funds. Analysts have mixed ratings, with one Buy, four Hold, and one Sell, and an average price target of $20.38. KALA BIO focuses on developing therapies for ocular diseases, including its FDA-approved product Eysuvis.</p>

KALA BIO (NASDAQ:KALA) Posts Quarterly Earnings Results